Abstract Background In the United States, mifepristone is available for medical abortion (for
use with misoprostol) only with Risk Evaluation and Mitigation Strategy (REMS) restrictions …

OBJECTIVES: Extensive data from clinical trials document mifepristone's safety and efficacy
for induced abortion, but less information is available about its safety in routine clinical use …

In September 2000, the Food and Drug Administration (FDA) approved mifepristone (also
known by the trade name Mifeprex or its original French name, RU-486) for use along with a …

PURPOSE Access to family planning health services in Canada has been historically
inadequate and inequitable. A potential solution appeared when Health Canada approved …

Background: The systematic analysis of morbidity and mortality for the Food and Drug
Administration (FDA)-approved medical abortion regimen using mifepristone is possible …

While pregnant women have sought abortifacients for thousands of years, they had no
success at finding one that both worked and did not jeopardize their lives in the process. The …

The requirement that mifepristone be dispensed only by physicians in offices, clinics or
hospitals—and not by prescription in pharmacies—has likely limited uptake by providers in …

Mifepristone medical abortion has been a valuable addition to the reproductive health
options of women. Aspects of its provision have however sometimes limited its accessibility …

BACKGROUND: The dose of mifepristone approved by most government agencies for
medical abortion is 600 mg. Our aim was to summarize extant data on the effectiveness and …

OBJECTIVE: To provide evidence regarding the safety, efficacy, and acceptability of 200 mg
mifepristone followed by home administration of 400 μg oral misoprostol METHODS: The …